UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages

Immunity (Cambridge, Mass.), 2022-08, Vol.55 (8), p.1386-1401.e10

2022

Volltextzugriff (PDF)

MDS overlap disorders and diagnostic boundaries

Blood, 2019-03, Vol.133 (10), p.1086-1095

2019

Volltextzugriff (PDF)

Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing

Frontiers in oncology, 2022-08, Vol.12, p.915629-915629

2022

Volltextzugriff (PDF)

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

Blood advances, 2019-10, Vol.3 (19), p.2845-2858

2019

Volltextzugriff (PDF)

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

Journal of clinical oncology, 2019-05, Vol.37 (15), p.1336-1351

2019

Volltextzugriff (PDF)

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

Journal of clinical oncology, 2023-05, Vol.41 (15), p.2815-2826

2023

Volltextzugriff (PDF)

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Journal of clinical oncology, 2023-11, Vol.41 (31), p.4893-4904

2023

Volltextzugriff (PDF)

Acute myeloid leukaemia evolving from essential thrombocythaemia with marked KMT2A amplification as a homogenously staining region

British journal of haematology, 2019-08, Vol.186 (4), p.509-509

2019

Volltextzugriff (PDF)

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update

Blood advances, 2019-04, Vol.3 (8), p.1197-1210

2019

Volltextzugriff (PDF)

A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia

Clinical lymphoma, myeloma and leukemia, 2018-05, Vol.18 (5), p.346-352.e5

2018

Volltextzugriff (PDF)

Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome

Cytotherapy (Oxford, England), 2021-03, Vol.23 (3), p.236-241

2021

Volltextzugriff (PDF)

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network, 2024-02, Vol.22 (1), p.43-69

2024

Volltextzugriff (PDF)

In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden

Cytotherapy (Oxford, England), 2021-04, Vol.23 (4), p.320-328

2021

Volltextzugriff (PDF)

SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes

Clinical lymphoma, myeloma and leukemia, 2017-10, Vol.17 (10), p.613-620

2017

Volltextzugriff (PDF)

Acute myeloid leukaemia evolving from essential thrombocythaemia with marked KMT 2A amplification as a homogenously staining region

British journal of haematology, 2019-08, Vol.186 (4), p.509-509

2019

Volltextzugriff (PDF)

Abstract 1894: Immunophenotypic and functional characterization of higher-risk MDS patient moDCs

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1894-1894

2021

Volltextzugriff (PDF)

A Prospective Randomized Clinical Trial Comparing a Calcineurin-Free Gvhd Prophylaxis Regimen with Post-Transplant Cyclophosphamide and Abatacept to Methotrexate and Tacrolimus

Blood, 2023-11, Vol.142 (Supplement 1), p.3551-3551

2023

Volltextzugriff (PDF)

DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of MDS

Blood, 2018-11, Vol.132 (Supplement 1), p.106-106

2018

Volltextzugriff (PDF)

T Cell Activation By OKT3 Is a Function of the Percent Monocytes in PBMC of Healthy Donors and MDS Patients

Blood, 2019-11, Vol.134 (Supplement_1), p.4870-4870

2019

Volltextzugriff (PDF)

Phenotypic and Proliferative Analysis of T Cell and Monocyte Populations in Patients with Intermediate/High/Very High-Risk MDS Compared to Age-Matched Healthy Donors

Blood, 2020-11, Vol.136 (Supplement 1), p.25-26

2020

Volltextzugriff (PDF)

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7020-7020

2022

Volltextzugriff (PDF)

Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7017-7017

2022

Volltextzugriff (PDF)

Methylation Profiling Among Patients with TET2 Mutations in Myelodysplastic Syndromes Is Associated with Overall Survival

Blood, 2016-12, Vol.128 (22), p.3158-3158

2016

Volltextzugriff (PDF)

A Phase 1 Clinical Trial of Personalized Adoptive Cellular Therapy Targeting Myelodysplastic Syndrome (MDS) Stem Cell Neoantigens (PACTN)

Blood, 2018-11, Vol.132 (Supplement 1), p.4373-4373

2018

Volltextzugriff (PDF)

Abstract 3352: A CRISPR-enabled function genomics profiling platform in acute leukemia: Updates from a pilot study of Function (Fx) Heme utilizing fresh patient samples

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.3352-3352

2024

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(26)
Buchkapitel
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(10)
Hematology
(8)
Oncology
(7)
Immunotherapy
(3)
Leukemia, Myeloid, Acute - Drug Therapy
(3)
Neoantigens
(3)
Treatment Outcome
(3)
Anemia - Drug Therapy
(2)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(2)
Azacitidine
(2)
Biotechnology & Applied Microbiology
(2)
Cell & Tissue Engineering
(2)
Cell Biology
(2)
Medicine, Research & Experimental
(2)
Mutation
(2)
Original Reports
(2)
Prognosis
(2)
Remission Induction
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages

MDS overlap disorders and diagnostic boundaries

Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Acute myeloid leukaemia evolving from essential thrombocythaemia with marked KMT2A amplification as a homogenously staining region

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update

A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia

Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden

SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes

Acute myeloid leukaemia evolving from essential thrombocythaemia with marked KMT 2A amplification as a homogenously staining region

Abstract 1894: Immunophenotypic and functional characterization of higher-risk MDS patient moDCs

A Prospective Randomized Clinical Trial Comparing a Calcineurin-Free Gvhd Prophylaxis Regimen with Post-Transplant Cyclophosphamide and Abatacept to Methotrexate and Tacrolimus

DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of MDS

T Cell Activation By OKT3 Is a Function of the Percent Monocytes in PBMC of Healthy Donors and MDS Patients

Phenotypic and Proliferative Analysis of T Cell and Monocyte Populations in Patients with Intermediate/High/Very High-Risk MDS Compared to Age-Matched Healthy Donors

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results

Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results

Methylation Profiling Among Patients with TET2 Mutations in Myelodysplastic Syndromes Is Associated with Overall Survival

A Phase 1 Clinical Trial of Personalized Adoptive Cellular Therapy Targeting Myelodysplastic Syndrome (MDS) Stem Cell Neoantigens (PACTN)

Abstract 3352: A CRISPR-enabled function genomics profiling platform in acute leukemia: Updates from a pilot study of Function (Fx) Heme utilizing fresh patient samples

Suchergebnisse filtern